Contact Us
Drug Search Results
More Filters [+]

Voruciclib

Alternative Names: voruciclib
Latest Update: 2024-11-12
Latest Update Note: News Article

Product Description

Voruciclib is a potent orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. (Sourced from: https://www.meipharma.com/pipeline/voruciclib)

Mechanisms of Action: CDK9 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: MEI Pharma
Company Location: SAN DIEGO CA 92130
Company CEO: Daniel P. Gold
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Voruciclib

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|B-Cell Marginal Zone Lymphoma|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Mantle-Cell Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ME-522-001

P1

Recruiting

Acute Lymphoid Leukemia|Follicular Lymphoma|B-Cell Marginal Zone Lymphoma|Diffuse Large B-Cell Lymphoma|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia

2024-04-30

27%

Recent News Events

Date

Type

Title

11/12/2024

News Article

 MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

08/12/2024

News Article

 MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

07/22/2024

News Article

 MEI Pharma to Consider Strategic Alternatives

05/09/2024

News Article

 MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

07/01/2020

PubMed

 Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials.

02/26/2020

PubMed

 Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions